The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Atara Biotherapeutics, Inc. Common Stock 046513107 14,619 1,876,650 SH   SOLE   1,876,650 0 0
Augmedix, Inc. Common Stock 05105P107 1 708 SH   SOLE   708 0 0
Rapt Therapeutics, Inc. Common Stock 75382E109 23,671 1,297,063 SH   SOLE   1,297,063 0 0
Twilio Inc. Class A Common Stock 90138F102 15,928 190,047 SH   SOLE   190,047 0 0